UNITED STATES 
 SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT 
 
 Pursuant to Section 13 or 15(d) of the 
 Securities Exchange Act of 1934 
 
 Date of Report (date of earliest event reported): September 7, 2011

OPEXA THERAPEUTICS, INC. 
 (Exact name of registrant as specified in its charter)

Texas	 	001-33004	 	76-0333165	
(State or other jurisdiction of
incorporation)		(Commission File Number)		(IRS Employer Identification
No.)	

2635 Technology Forest Blvd., The Woodlands, Texas	77381	
(Address of principal executive offices)	(Zip Code)	

Registrant’s telephone number, including area code: (281) 272-9331	
N/A	
(Former name or former address, if changed since last report)	

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⃞       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01	Other Events	
On September 7, 2011, Opexa Therapeutics, Inc. (the “ Company ”) issued a press release announcing that Neil K. Warma, the Company’s President and Chief Executive Officer, will deliver a corporate presentation at the Rodman & Renshaw Annual Global Investment Conference – Healthcare.  The Company’s presentation will take place at 11:40 a.m. (ET) on Tuesday, September 13, 2011, in the Metropolitan East of The Waldorf Astoria Hotel in New York City.  The presentation will include an overview of the Company’s ongoing clinical development program for Tovaxin®, the Company’s lead therapy for multiple sclerosis.  The presentation will be webcasted and the link to access the audio webcast and the presentation materials will be available at the Investor Relations page of the Company’s website at www.opexatherapeutics.com.

Item 9.01	Financial Statements and Exhibits	

(d) Exhibits	
 	
Exhibit No.	Description	
 	
99.1	Press release issued September 7, 2011 by Opexa Therapeutics, Inc.	

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated:	September 12, 2011	OPEXA THERAPEUTICS, INC.	

		By:	/s/ Neil K. Warma		
			Neil K. Warma	
			President & Chief Executive Officer	

3

Exhibit Index

Exhibit No.	Description	
	 	
99.1	Press release issued September 7, 2011 by Opexa Therapeutics, Inc.	

Exhibit 99.1
Opexa to Present at the Rodman & Renshaw Annual Global Investment 
 Conference - Healthcare on September 13, 2011
THE WOODLANDS, Texas--(BUSINESS WIRE)--September 7, 2011-- Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced that Neil K. Warma, Opexa’s President and Chief Executive Officer, will deliver a corporate presentation at the Rodman & Renshaw Annual Global Investment Conference - Healthcare. The conference will be held September 11-13 at The Waldorf Astoria in New York City.
Opexa’s presentation will occur at 11:40 a.m. (EDT) on Tuesday, September 13, 2011 in Metropolitan East of The Waldorf Astoria Hotel and will include an overview of the Company’s ongoing clinical development program for Tovaxin, the Company’s lead therapy for MS. The presentation will be webcasted and the link to access the audio webcast and presentation will be available at the Investor Relations page of the Company’s website at www.opexatherapeutics.com .
About Opexa
Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. The Company’s leading therapy, Tovaxin®, is a personalized cellular immunotherapy treatment that is in late stage clinical development for MS. Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time.
Opexa is preparing for a Phase III clinical trial with Tovaxin in Relapsing-Remitting Multiple Sclerosis (RRMS) following the completion of a Phase IIb clinical study in 150 patients with MS. Data from this clinical study show evidence that RRMS patients treated with Tovaxin saw overall clinical and disability benefits over the placebo group, including a clinically relevant decrease in the Annualized Relapse Rate (ARR), and improvement in disability score (EDSS), as well as an excellent safety profile with no serious adverse events related to Tovaxin treatment. In addition, Opexa is evaluating opportunities to advance Tovaxin through clinical development in Secondary Progressive Multiple Sclerosis (SPMS), an area with high unmet medical need.
For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com .
CONTACT:
Opexa Therapeutics, Inc.
Neil K. Warma, 281-775-0600
nwarma@opexatherapeutics.com